Nine newly identified individuals refine the phenotype associated with MYT1L mutations.


Journal

American journal of medical genetics. Part A
ISSN: 1552-4833
Titre abrégé: Am J Med Genet A
Pays: United States
ID NLM: 101235741

Informations de publication

Date de publication:
05 2020
Historique:
received: 07 11 2019
revised: 16 01 2020
accepted: 28 01 2020
pubmed: 18 2 2020
medline: 13 1 2021
entrez: 18 2 2020
Statut: ppublish

Résumé

Both point mutations and deletions of the MYT1L gene as well as microdeletions of chromosome band 2p25.3 including MYT1L are associated with intellectual disability, obesity, and behavioral problems. Thus, MYT1L is assumed to be the-at least mainly-causative gene in the 2p25.3 deletion syndrome. Here, we present comprehensive descriptions of nine novel individuals bearing MYT1L mutations; most of them single nucleotide variants (SNVs). This increases the number of known individuals with causative deletions or SNVs of MYT1L to 51. Since eight of the nine novel patients bear mutations affecting MYT1L only, the total number of such individuals now nearly equals the number of individuals with larger microdeletions affecting additional genes, allowing for a comprehensive phenotypic comparison of these two patient groups. For example, 55% of the individuals with mutations affecting MYT1L only were overweight or obese as compared to 86% of the individuals with larger microdeletions. A similar trend was observed regarding short stature with 5 versus 35%, respectively. However, these differences were nominally significant only after correction for multiple testing, further supporting the hypothesis that MYT1L haploinsufficiency is central to the 2p25.3 deletion phenotype. Most importantly, the large number of individuals with MYT1L mutations presented and reviewed here allowed for the delineation of a more comprehensive clinical picture. Seizures, postnatal short stature, macrocephaly, and microcephaly could be shown to be over-represented among individuals with MYT1L mutations.

Identifiants

pubmed: 32065501
doi: 10.1002/ajmg.a.61515
doi:

Substances chimiques

MYT1L protein, human 0
Nerve Tissue Proteins 0
Transcription Factors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1021-1031

Informations de copyright

© 2020 The Authors. American Journal of Medical Genetics Part A published by Wiley Periodicals, Inc.

Références

Al Tuwaijri, A., & Alfadhel, M. (2019). MYT1L mutation in a patient causes intellectual disability and early onset of obesity: A case report and review of the literature. Journal of Pediatric Endocrinology and Metabolism, 32(4), 409-413.
Becker, K., Jaggard, C., & Horrocks, S. (2010). A novel presentation of a rare chromosome 2p25.2 deletion. Clinical Dysmorphology, 19(2), 101-102. https://doi.org/10.1097/MCD.0b013e328337bb28
Blanchet, P., Bebin, M., Bruet, S., Cooper, G. M., Thompson, M. L., Duban-Bedu, B., … McNeill, A. (2017). MYT1L mutations cause intellectual disability and variable obesity by dysregulating gene expression and development of the neuroendocrine hypothalamus. PLOS Genetics, 13(8), e1006957. https://doi.org/10.1371/journal.pgen.1006957
Bonaglia, M. C., Giorda, R., & Zanini, S. (2014). A new patient with a terminal de novo 2p25.3 deletion of 1.9 Mb associated with early-onset of obesity, intellectual disabilities and hyperkinetic disorder. Molecular Cytogenetics, 7, 53. https://doi.org/10.1186/1755-8,166-7-53
Coban-Akdemir, Z., White, J. J., Song, X., Jhangiani, S. N., Fatih, J. M., Gambin, T., … Carvalho, C. M. B. (2018). Identifying genes whose mutant transcripts cause dominant disease traits by potential gain-of-function alleles. American Journal of Human Genetics, 103(2), 171-187. https://doi.org/10.1016/j.ajhg.2018.06.009
de Ligt, J., Willemsen, M. H., van Bon, B. W., Kleefstra, T., Yntema, H. G., Kroes, T., … Vissers, L. E. (2012). Diagnostic exome sequencing in persons with severe intellectual disability. The New England Journal of Medicine, 367(20), 1921-1929. https://doi.org/10.1056/NEJMoa1206524
de Onis, M., & Lobstein, T. (2010). Defining obesity risk status in the general childhood population: Which cut-offs should we use? International Journal of Pediatric Obesity, 5(6), 458-460. https://doi.org/10.3109/17477161003615583
De Rocker, N., Vergult, S., Koolen, D., Jacobs, E., Hoischen, A., Zeesman, S., … Menten, B. (2015). Refinement of the critical 2p25.3 deletion region: The role of MYT1L in intellectual disability and obesity. Genetics in Medicine, 17(6), 460-466. https://doi.org/10.1038/gim.2014.124
den Dunnen, J. T., & Antonarakis, S. E. (2000). Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion. Human Mutation, 15(1), 7-12. https://doi.org/10.1002/(SICI)1098-1004(200001)15:1<7::AID-HUMU4>3.0.CO;2-N
Den, K., Kato, M., Yamaguchi, T., Miyatake, S., Takata, A., Mizuguchi, T., … Matsumoto, N. (2019). A novel de novo frameshift variant in SETD1B causes epilepsy. Journal of Human Genetics, 64(8), 821-827. https://doi.org/10.1038/s10038-019-0617-1
Doco-Fenzy, M., Leroy, C., Schneider, A., Petit, F., Delrue, M. A., Andrieux, J., … Genevieve, D. (2014). Early-onset obesity and paternal 2pter deletion encompassing the ACP1, TMEM18, and MYT1L genes. European Journal of Human Genetics, 22(4), 471-479. https://doi.org/10.1038/ejhg.2013.189
Hempel, M., Cremer, K., Ockeloen, C. W., Lichtenbelt, K. D., Herkert, J. C., Denecke, J., … Lessel, D. (2015). De novo mutations in CHAMP1 cause intellectual disability with severe speech impairment. American Journal of Human Genetics, 97(3), 493-500. https://doi.org/10.1016/j.ajhg.2015.08.003
Hiraide, T., Nakashima, M., Yamoto, K., Fukuda, T., Kato, M., Ikeda, H., … Saitsu, H. (2018). De novo variants in SETD1B are associated with intellectual disability, epilepsy and autism. Human Genetics, 137(1), 95-104. https://doi.org/10.1007/s00439-017-1863-y
Kircher, M., Witten, D. M., Jain, P., O'Roak, B. J., Cooper, G. M., & Shendure, J. (2014). A general framework for estimating the relative pathogenicity of human genetic variants. Nature Genetics, 46(3), 310-315. https://doi.org/10.1038/ng.2892
Loid, P., Makitie, R., Costantini, A., Viljakainen, H., Pekkinen, M., & Makitie, O. (2018). A novel MYT1L mutation in a patient with severe early-onset obesity and intellectual disability. American Journal of Medical Genetics - Part A, 176(9), 1972-1975. https://doi.org/10.1002/ajmg.a.40370
Mayo, S., Rosello, M., Monfort, S., Oltra, S., Orellana, C., & Martinez, F. (2015). Haploinsufficiency of the MYT1L gene causes intellectual disability frequently associated with behavioral disorder. Genetics in Medicine, 17(8), 683-684. https://doi.org/10.1038/gim.2015.86
Rio, M., Royer, G., Gobin, S., de Blois, M. C., Ozilou, C., Bernheim, A., … Malan, V. (2013). Monozygotic twins discordant for submicroscopic chromosomal anomalies in 2p25.3 region detected by array CGH. Clinical Genetics, 84(1), 31-36. https://doi.org/10.1111/cge.12036
Schafgen, J., Cremer, K., Becker, J., Wieland, T., Zink, A. M., Kim, S., … Engels, H. (2016). De novo nonsense and frameshift variants of TCF20 in individuals with intellectual disability and postnatal overgrowth. European Journal of Human Genetics, 24(12), 1,739-1,745. https://doi.org/10.1038/ejhg.2016.90
Stevens, S. J., van Ravenswaaij-Arts, C. M., Janssen, J. W., Klein Wassink-Ruiter, J. S., van Essen, A. J., Dijkhuizen, T., … Engelen, J. J. (2011). MYT1L is a candidate gene for intellectual disability in patients with 2p25.3 (2pter) deletions. American Journal of Medical Genetics - Part A, 155a(11), 2739-2745. https://doi.org/10.1002/ajmg.a.34274
Wang, T., Guo, H., Xiong, B., Stessman, H. A., Wu, H., Coe, B. P., … Eichler, E. E. (2016). De novo genic mutations among a Chinese autism spectrum disorder cohort. Nature Communications, 7, 13316. https://doi.org/10.1038/ncomms13316ncomms13316
Youssefian, L., Vahidnezhad, H., Saeidian, A. H., Pajouhanfar, S., Sotoudeh, S., Mansouri, P., … Uitto, J. (2019). Inherited non-alcoholic fatty liver disease and dyslipidemia due to monoallelic ABHD5 mutations. Journal of Hepatology, 71, 366-370. https://doi.org/10.1016/j.jhep.2019.03.026

Auteurs

Isabelle C Windheuser (IC)

Institute of Human Genetics, University of Bonn, University Hospital Bonn, Bonn, Germany.

Jessica Becker (J)

Institute of Human Genetics, University of Bonn, University Hospital Bonn, Bonn, Germany.

Kirsten Cremer (K)

Institute of Human Genetics, University of Bonn, University Hospital Bonn, Bonn, Germany.

Hela Hundertmark (H)

Institute of Human Genetics, University of Bonn, University Hospital Bonn, Bonn, Germany.

Laura M Yates (LM)

Northern Genetics Service, Institute of Genetic Medicine, International Centre for Life, Central Parkway, Newcastle upon Tyne, UK.
Laura M. Yates, Inkosi Albert Letholi Central Hospital and KRISP, University of KwaZulu-Natal, KwaZulu-Natal, South Africa.

Elisabeth Mangold (E)

Institute of Human Genetics, University of Bonn, University Hospital Bonn, Bonn, Germany.

Sophia Peters (S)

Institute of Human Genetics, University of Bonn, University Hospital Bonn, Bonn, Germany.

Franziska Degenhardt (F)

Institute of Human Genetics, University of Bonn, University Hospital Bonn, Bonn, Germany.
Department of Genomics, Life & Brain Center, Rheinische Friedrich-Wilhelms-University, Bonn, Germany.

Kerstin U Ludwig (KU)

Institute of Human Genetics, University of Bonn, University Hospital Bonn, Bonn, Germany.
Department of Genomics, Life & Brain Center, Rheinische Friedrich-Wilhelms-University, Bonn, Germany.

Alexander M Zink (AM)

Institute of Human Genetics, University of Bonn, University Hospital Bonn, Bonn, Germany.
Department of Genomics, Life & Brain Center, Rheinische Friedrich-Wilhelms-University, Bonn, Germany.

Davor Lessel (D)

Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Tatjana Bierhals (T)

Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Theresia Herget (T)

Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Jessika Johannsen (J)

Department of Pediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Jonas Denecke (J)

Department of Pediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Eva Wohlleber (E)

Institute of Human Genetics, University of Bonn, University Hospital Bonn, Bonn, Germany.

Tim M Strom (TM)

Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany.

Dagmar Wieczorek (D)

Institut für Humangenetik, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
Institut für Humangenetik, Universitätsklinikum Essen, Essen, Germany.

Marta Bertoli (M)

Northern Genetics Service, Institute of Genetic Medicine, International Centre for Life, Central Parkway, Newcastle upon Tyne, UK.

Roberto Colombo (R)

Faculty of Medicine "Agostino Gemelli", Catholic University of the Sacred Heart, Rome, Italy.
Center for the Study of Rare Hereditary Diseases, CeSMER, Niguarda Ca' Granda Metropolitan Hospital, Milan, Italy.

Maja Hempel (M)

Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Hartmut Engels (H)

Institute of Human Genetics, University of Bonn, University Hospital Bonn, Bonn, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH